Pfizer (PFE) – Get report and its German partner BioNTech (BNTX) – Get report were increased in premarth trade Friday after the companies said their Covid-19 vaccine candidate would pass tests in the final stage.
The companies said the vaccine was “well tolerated with mild to moderate fever in less than 20% of participants.”
Pfizer and BioNTech said last Thursday that they are continuing to analyze data from Phase 1 trials in the US and Germany.
“The full body of clinical and preclinical data informs Pfizer and BioNTech’s decision to select BNT162b2 as the lead candidate to continue in pivotal trials,” said Kathrin U. Jansen, senior vice president of Pfizer and head of fax research and development .
Pfizer rose 1.24% to $ 39.20 in premium trading and BioNTech jumped 8.63% to $ 71.99.
Pfizer agreed last month to deliver 600 million doses of its coronavirus vaccine to the US government. Pfizer and BioNTech will receive $ 1.95 billion for the first 100 million doses of their BNT162b2 vaccine, once approved by regulators, with the potential for a further 500 million doses to be produced thereafter.
More than 160 coronavirus vaccines are under development worldwide, according to the World Health Organization.
Johnson and Johnson (JNJ) – Get report next month it is likely to start testing a late-stage trial of a potential coronavirus vaccine.
The Phase 3 trial would enroll up to 60,000 healthy people aged 18 and older across nearly 180 locations in the U.S. and other countries, according to ClinicalTrials.gov, a U.S. government database of clinical trials, and CNBC.
“Our Phase 3 program is designed to be as robust as possible, can accommodate up to 60,000 participants and will be conducted in places with high incident rates,” Jake Sargent spokeswoman Jake Sargent said in a statement to CNBC.
“We use epidemiology and modeling data to predict and plan where our studies should take place and expect these to be finalized shortly.”
Participants will be randomly selected to receive a dose of the potential vaccine as a placebo.
.
